• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Modulating lymphocyte populations decreases graft rejection in mice

bySarah StapletonandChaz Carrier
May 22, 2014
in Chronic Disease
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

Image: PD 

1. A combination therapy of Campath, Rapamycin, and anti-IL-7 receptor blocking antibody induced tolerance of mismatched skin grafts in mice. 

2. This combination therapy preferentially enriched T regulatory cells in a reconstituted T cell population. 

Study Rundown: While early animal studies suggested that T cell depletion before allotransplantation promoted graft tolerance, similar studies in humans have not found such success. The homeostatic proliferation of T cells following depletion results in a renewed population of effector and regulatory T cells. Effector T cells are believed to drive graft rejection while regulatory T cells (Tregs) suppress such immune responses and are necessary for tolerance of transplants. It has been proposed that, after T cell depletion, biasing the T cell reconstituted population toward Tregs may reduce transplant rejections.

In this study, researchers investigated the mean survival time and tolerance of MHC mismatched skin grafts in mice. They found that depletion of the T cells alone using Campath (alemtuzumab) did not promote graft tolerance, with all grafts eventually rejected. Campath treatment followed by antibody blocking of effector T cell activity greatly enhanced graft tolerance. This study further examined the potential to control the population of T cells post ablation by targeting IL-7R and mammalian target of rapamycin (mTOR), both associated with T cell repopulation and activation. Combination treatment of blocking antibody against IL-7R (αIL-7R) and mTOR inhibitor Rapamycin after T cell depletion delayed graft rejection in one mouse model and induced tolerance in another. This treatment was shown to enrich the repopulated T cells for Tregs and to suppress expansion of some effector T cells. The tolerance effect of the combination therapy was shown to be dependent on TGF-β. Despite the short-term nature of this murine study (max survival study length: 200 days), the results show a clear benefit in early graft tolerance.

Click to read the study in the American Journal of Transplantation

Relevant Reading: Homeostatic proliferation of lymphocytes results in augmented memory-like function and accelerated allograft rejection

RELATED REPORTS

BNT162b2 booster is safe and reduces COVID-19 transmission in older adults

Bisphosphonates, denosumab, abaloparatide, teriparatide, and romosozumab reduce postmenopausal fracture risk

Epstein-Barr viral load monitoring reduces risk of post-liver transplant lymphoproliferative disease

In-Depth [animal study]: This study examined the survival time of MHC mismatched skin grafts in homozygous and heterozygous mice transgenic for hCD52 expression in T cells. Graft survival studies were completed over periods of time ranging 50 to 200 days. During transplantation, full thickness tail-skin was grafted to the thoracic flank of the recipient mouse. Rejection was considered when no donor skin was visible at the suture site. Tolerance was defined as graft survival greater than study length. T cell populations were evaluated from pooled spleens and nodes and in vivo T cell proliferation was evaluated using two separate in vivo labeling and sorting procedures. Graft survival events and significance were evaluated by log-rank Mantel-Cox tests. Comparisons among were made using one-way analysis of variance and Bonferroni’s posttests. Campath treatment followed by αIL-7R and Rapamycin (combination therapy) significantly increased graft mean survival time (MST) when compared to Campath treatment followed by Rapamycin alone (MST 56 days, p = 0.001). Combination therapy also increased tolerance, with two thirds of mice exhibiting MST > 100 days. T cell populations after combination therapy were enriched for Foxp3+ Tregs by reduced presences of CD4+ and CD8+ effector T cells. Neutralization of TGF-β significantly decreased graft survival time in mice treated with combination therapy (p = 0.032) and no tolerance events occurred.

More from this author: Adding Evolocumab to statin therapy further decreases LDL-C levels, Genetic variant linked to poor patient survival following lung transplantation, Genetic variations may predict outcomes for colorectal cancer patients, Neuroendocrine tumor marker pancreastatin may be predictive of survival, Initial kidney transplant factors may provide insight into retransplant success

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.

Previous Post

Higher cost-sharing associated with delayed care for children’s asthma

Next Post

Lower rates of repeat intervention following ureteroscopy for kidney stones

RelatedReports

Social networks play key roles in parental vaccination decisions
Infectious Disease

BNT162b2 booster is safe and reduces COVID-19 transmission in older adults

January 30, 2023
Romosozumab significantly increases bone mineral density in postmenopausal women
Chronic Disease

Bisphosphonates, denosumab, abaloparatide, teriparatide, and romosozumab reduce postmenopausal fracture risk

January 30, 2023
Resection of colorectal liver metastases may improve cost and longevity
Chronic Disease

Epstein-Barr viral load monitoring reduces risk of post-liver transplant lymphoproliferative disease

January 30, 2023
Quick Take: State Gun Laws, Gun Ownership, and Mass Shootings in the US: Cross-Sectional Time Series
Pediatrics

Homicide deaths are on the rise for children living in the United States

January 30, 2023
Next Post
Renal stones in women linked with increased risk of coronary heart disease

Lower rates of repeat intervention following ureteroscopy for kidney stones

APOL1 variants linked to increased risk of renal disease among black patients

New device for continuous renal replacement therapy in small infants

H. Pylori infection influenced by genes

Asymptomatic H. pylori eradication decreased gastric cancer in Asian populations

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • BNT162b2 booster is safe and reduces COVID-19 transmission in older adults
  • Bisphosphonates, denosumab, abaloparatide, teriparatide, and romosozumab reduce postmenopausal fracture risk
  • Epstein-Barr viral load monitoring reduces risk of post-liver transplant lymphoproliferative disease
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options